Ai-Driven Prediction of Adverse Drug Reactions: Clinical Pattern Analysis and Risk Assessment

Adverse Drug Reactions (ADRs) are defined by the World Health Organization (WHO) as "noxious and unintended responses to a drug at doses normally used in humans" (WHO, 1972). They represent one of the most significant yet preventable burdens on global healthcare systems. Epidemiological evidence consistently positions ADRs among the fourth and sixth leading causes of mortality worldwide, comparable in impact to major diseases such as heart disease, cancer, and stroke [Backman et al., 2023]. The scale of ADR-related harm is staggering. In European Union member states, ADRs cause approximately 197,000 deaths annually, with median hospital admission rates of 3.5% and in-hospital ADR occurrence rates of 10.1% across prospective epidemiological studies [Bouvy et al., 2015]. In the United States, ADRs account for 5–10% of all hospital admissions, with an overall incidence of serious ADRs reaching 6.7% and fatal ADRs at 0.32% among hospitalized patients [Seo et al., 2023]. Globally, approximately 16.9% of hospitalized patients experience an ADR during their stay [Rothschild et al., 2010]. The economic burden compounds this human toll—direct costs include prolonged hospitalization, additional interventions, and emergency visits, while indirect costs encompass lost productivity and long-term disability. Despite this recognized burden, conventional pharmacovigilance systems are fundamentally reactive and structurally limited. The Yellow Card Scheme (UK), MedWatch (USA), and WHO VigiBase represent passive, voluntary reporting systems characterized by severe underreporting—estimated at over 90% in most settings—and significant temporal gaps between ADR occurrence and signal detection [Al Meslamani, 2023]. Signal detection algorithms such as the Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) offer statistical screening but cannot contextualize individual patient risk profiles or predict reactions prior to drug exposure. The emergence of artificial intelligence and machine learning technologies offers a transformative opportunity to reconceptualize pharmacovigilance from a reactive surveillance paradigm to a proactive, predictive framework. The exponential growth of structured and unstructured clinical data—Electronic Health Records (EHRs), genomic databases, spontaneous reporting systems, social media, and wearable sensor streams—creates an unprecedented substrate for AI-driven risk modeling. Machine learning algorithms can identify subtle, high-dimensional patterns across thousands of clinical variables simultaneously, uncovering risk signatures that are invisible to conventional statistical approaches. Recent years have witnessed rapid methodological diversification in AI-based ADR research. Classical supervised learning models (random forests, gradient boosting, support vector machines) have been succeeded by deep learning architectures employing convolutional and recurrent neural networks, transformer-based language models including BERT and GPT variants, and graph neural networks capable of modeling complex drug-drug and drug-patient interaction networks [Hu et al., 2024; Li et al., 2024; Gao et al., 2024]. Simultaneously, explainable AI (XAI) frameworks—particularly SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations)—are bridging the gap between model performance and clinical interpretability [Salih et al., 2025]. This paper provides a comprehensive synthesis of the state-of-the-art in AI-driven ADR prediction, organized around five thematic pillars: (1) the epidemiological and clinical burden of ADRs; (2) classical ML approaches and their performance benchmarks; (3) deep learning and NLP methodologies; (4) graph neural network architectures for relational drug-patient modeling; and (5) XAI, pharmacogenomics, and translational integration into clinical decision support systems. We conclude with a critical appraisal of current limitations and a research agenda for the next decade.

Epidemiology And Clinical Burden of Adr

The global burden of ADRs constitutes a major public health emergency that has persisted despite decades of pharmacovigilance effort. Epidemiological evidence accumulated over the past three decades reveals a consistent pattern of high incidence, preventability, and healthcare system impact across diverse healthcare settings worldwide. In developed healthcare systems, the median prevalence of ADR-related hospitalization ranges from 3.3% to 11.0% (median 6.3%), while in developing countries the corresponding range is 1.1% to 16.9% (median 5.5%) [Kongkaew et al., 2016]. The comparability of these figures across high- and low-income settings underscores the universality of the ADR challenge, irrespective of healthcare system maturity. Critically, the proportion of preventable ADRs in developed countries reaches 71.7% (IQR 62.3–80.0%), indicating that the majority of ADR-related harm is potentially avoidable [Kongkaew et al., 2016].

Age-related vulnerability represents a particularly significant dimension of ADR epidemiology. Elderly patients (aged ≥65 years) are disproportionately represented in ADR incidence data due to multiple intersecting mechanisms: age-related pharmacokinetic changes (reduced renal clearance, altered hepatic metabolism, decreased protein binding), higher prevalence of polypharmacy, increased pharmacodynamic sensitivity, and greater comorbidity burden. A U.S. study estimates approximately 22% of adults aged 40–79 take five or more medications concurrently—a pattern strongly associated with heightened ADR risk [Marques-Garcia et al., 2026]. The economic dimensions of ADR burden are equally substantial. Direct costs attributable to ADR-related hospitalizations, extended lengths of stay, and additional diagnostic and therapeutic interventions impose enormous pressure on healthcare budgets. A comprehensive cost-of-illness analysis indicates that drug-related morbidity and mortality represent billions of dollars in annual direct healthcare costs in the United States alone. Additional indirect costs arise from lost productivity, disability, and premature mortality.

Classification Frameworks for ADRs

Systematic classification of ADRs is foundational to both clinical management and AI-based prediction modeling. The most widely adopted taxonomic framework distinguishes ADR types by mechanism, predictability, and dose-dependency.

The Rawlins-Thompson classification divides ADRs into Type A (Augmented), representing dose-dependent, pharmacologically predictable extensions of the drug's known mechanism, and Type B (Bizarre), which are dose-independent, idiosyncratic reactions often mediated by immunological or pharmacogenomic mechanisms. Subsequent extensions introduced Types C (Chronic, related to long-term exposure), D (Delayed, emerging after treatment cessation), E (End-of-use, withdrawal reactions), and F (Failure of therapy). The DoTS (Dose, Time-course, Susceptibility) classification provides a more granular framework applicable to clinical risk stratification. For AI modeling purposes, the MedDRA (Medical Dictionary for Regulatory Activities) coding system provides the operational taxonomy through which ADRs are recorded in spontaneous reporting databases including FAERS and VigiBase. The System Organ Class (SOC) hierarchy within MedDRA enables both signal detection and supervised model training across standardized, granular adverse event categories. Table 1 summarizes the most commonly predicted ADR categories from recent machine learning studies.

Table 1. Most Commonly Predicted ADR Categories in Machine Learning Studies (2020–2025)

Classic Machine Learning Approach

 Random Forest and Ensemble Methods

Classical supervised machine learning methods constitute the most extensively validated category of AI approaches in ADR prediction research. A 2024 systematic review and meta-analysis by Hu et al., encompassing studies from PubMed, Web of Science, Embase, and IEEE Xplore through November 2023, identified 10 high-quality studies employing 20 distinct ML methods for predicting multiple adverse drug events from EHR data [Hu et al., 2024]. Random forest (RF) emerged as the most commonly deployed algorithm (n=9 studies), followed by AdaBoost (n=4), eXtreme Gradient Boosting/XGBoost (n=3), and Support Vector Machine/SVM (n=3). The mean area under the ROC curve (AUC) across all included studies was 0.76 (95% CI: 0.26–0.95), with a pooled estimated AUC of 0.72 (95% CI: 0.68–0.75) [Hu et al., 2024]. Notably, random forest models combined with resampling-based approaches to address class imbalance achieved the highest documented AUCs in the reviewed literature, reaching 0.9448–0.9457. The superiority of ensemble methods in ADR prediction contexts reflects several intrinsic algorithmic advantages. Random forests' capacity to handle high-dimensional EHR feature spaces (often comprising hundreds of clinical variables), their robustness to missing data, and their inherent feature importance metrics render them particularly suited to clinical prediction tasks. Gradient boosting methods including XGBoost and LightGBM further improve on base RF performance through sequential error minimization, demonstrating particular strength in structured tabular clinical data. Feature importance analyses across RF and ensemble studies consistently identify common risk determinants of ADEs: (1) length of hospital stay; (2) number of prescribed drugs (polypharmacy index); (3) admission type; (4) age and sex; (5) renal function markers (serum creatinine, eGFR); (6) hepatic function markers (ALT, AST, bilirubin); and (7) prior ADR history [Hu et al., 2024]. These clinically interpretable risk factors provide a foundation for translating model outputs into actionable clinical decision support.

Support Vector Machines and Logistic Regression

Support Vector Machines (SVMs) have demonstrated consistent utility in ADR prediction tasks involving chemical structure-based features, pharmacological descriptors, and binary outcome classification. Their strength lies in effective margin maximization in high-dimensional feature spaces, rendering them suitable for molecular descriptor-based prediction of drug toxicity profiles. In clinical applications employing FAERS demographic and drug characteristic data, SVM models achieved accuracy rates of approximately 80%, compared to 78% for logistic regression and 85% for more complex CNN architectures [AI-driven pharmacovigilance, 2025]. Logistic regression, despite its comparative simplicity, remains a relevant baseline and clinical decision tool due to its inherent interpretability, calibration properties, and regulatory acceptability. In contexts where feature-outcome relationships are approximately linear and clinical transparency is paramount, logistic regression models enriched with interaction terms offer practical value. The LASSO (Least Absolute Shrinkage and Selection Operator) variant provides automatic variable selection, addressing multicollinearity in high-dimensional EHR data.

Class Imbalance and Data Quality Challenges

A fundamental challenge confronting all supervised ML approaches in ADR prediction is severe class imbalance: adverse reactions typically represent a minority class, often comprising 1–15% of the training dataset. Uncorrected imbalance results in classifiers heavily biased toward the majority non-ADR class, generating misleadingly high overall accuracy while providing poor ADR sensitivity—precisely the metric of greatest clinical relevance. Established remediation strategies include oversampling techniques (SMOTE—Synthetic Minority Oversampling TEchnique, ADASYN), undersampling of the majority class, cost-sensitive learning with asymmetric misclassification penalties, and ensemble methods specifically designed for imbalanced data (BalancedBaggingClassifier, EasyEnsemble). The combination of RF with resampling approaches achieving AUCs of 0.94 exemplifies the performance gains attainable through appropriate imbalance handling [Hu et al., 2024]. Data quality represents a complementary challenge. EHR data suffer from incompleteness, inconsistent coding practices across institutions, temporal misalignment between drug exposure and outcome recording, and confounding by indication (patients receiving specific drugs may have baseline conditions that independently predict the outcome). FAERS and VigiBase data introduce additional complexities including duplicate reports, unverified diagnoses, and variable reporter expertise. Rigorous preprocessing pipelines—encompassing imputation, standardization, deduplication, and temporal feature engineering—are prerequisite to reliable model development.

Deep Learning Architecture for Adr Prediction

Convolutional and Recurrent Neural Networks

Deep learning architectures have substantially expanded the representational capacity of AI-based ADR prediction beyond the constraints of handcrafted features. Convolutional Neural Networks (CNNs), originally developed for image recognition, have been adapted for ADR prediction from molecular structures (treating chemical fingerprints as 1D sequences), sequential clinical events, and multimodal clinical data integration. A hybrid AI-driven framework integrating structured data (demographics, lab results) with unstructured clinical notes via CNN achieved an accuracy of 85%, outperforming traditional models including Logistic Regression (78%) and SVM (80%) [AI-driven pharmacovigilance, 2025]. Recurrent Neural Networks (RNNs), particularly Long Short-Term Memory (LSTM) networks and bidirectional LSTMs, capture temporal dependencies in longitudinal clinical data—a critical capability for modeling ADR trajectories over time. The ability of LSTM architectures to learn which elements of a patient's clinical history (medication sequences, laboratory trends, vital sign trajectories) are predictive of future ADR occurrence makes them especially well-suited to EHR-based risk modeling. Bidirectional LSTMs process sequential input in both forward and backward temporal directions, enabling richer contextual feature extraction. Attention mechanisms, originally introduced in the context of machine translation, have been incorporated into deep learning ADR models to provide interpretable feature weighting across time steps. Attention weights indicate which temporal events or clinical measurements most strongly influenced a given prediction, offering a layer of mechanistic interpretability that raw neural network outputs typically lack.

Transformer Architectures and Large Language Models

The introduction of the transformer architecture (Vaswani et al., 2017) and its subsequent biomedical adaptations has created a paradigm shift in clinical NLP and text-based ADR detection. BERT (Bidirectional Encoder Representations from Transformers) and its domain-adapted variants—BioBERT, ClinicalBERT, PubMed BERT—have demonstrated state-of-the-art performance in clinical NLP tasks including named entity recognition, relation extraction, and adverse event detection from clinical narratives [Dong et al., 2024]. ClinicalBERT, pre-trained on large-scale MIMIC-III clinical notes, employs a 12-layer transformer architecture with 110 million parameters and captures clinical terminology and semantic nuances absent from general-domain BERT models. Applied to ADR detection tasks, ClinicalBERT and its variants demonstrate performance advantages of 5–10% accuracy over previously published NLP models [McMaster et al., 2023]. In a pilot study of serious adverse event (SAE) identification from outpatient inflammatory bowel disease notes, the UCSF-BERT model achieved accuracy of 88–92% with macro F1 scores of 61–68% [Nishioka et al., 2024]. BERT-based models applied to social media pharmacovigilance—extracting ADR mentions from Twitter/X, patient forums, and drug review websites—have demonstrated precision improvements of 15–20% over rule-based NLP baselines [Dong et al., 2024]. Social media platforms provide near-real-time surveillance data from patient-reported experiences, offering complementary coverage to formal spontaneous reporting systems. The FDA has recognized the pharmacovigilance value of social media data, with NLP analysis of VAERS COVID-19 vaccine reports demonstrating the applicability of transformer models to signal validation workflows [Artificial Intelligence in Pharmacovigilance, 2025]. The emergence of generative large language models (GPT-4, Llama, Gemini) introduces new capabilities for ADR prediction including zero-shot and few-shot learning, cross-lingual pharmacovigilance, and conversational clinical decision support. A 2025 narrative review synthesizing LLM applications to adverse drug event detection found that chatbot-assisted systems have been explored as tools in clinical management, aiding medication adherence monitoring and symptom surveillance [LLMs for ADEs, 2025]. However, LLM-specific challenges including hallucination, knowledge cutoff limitations, and lack of calibrated uncertainty remain barriers to clinical deployment.

Natural Language Processing for Clinical Text Mining

Structured vs. Unstructured Data in ADR Detection

A critical insight driving NLP adoption in pharmacovigilance is the recognition that the majority of clinically actionable ADR information resides not in structured database fields but in free-text clinical narratives—physician notes, discharge summaries, pharmacy records, and nursing documentation. A 2025 scoping review found that NLP/ML techniques applied to unstructured EHR data significantly improved detection of under-reported adverse events and safety signals that would not have been apparent through structured data alone [McMaster et al., 2023; NLP/ML Scoping Review, 2025].

The pipeline for NLP-based ADR detection from clinical text encompasses: (1) preprocessing (tokenization, normalization, de-identification); (2) named entity recognition (NER) to identify drug names and adverse event mentions; (3) relation extraction to link drug-ADR pairs; (4) negation and speculation detection to exclude non-positive assertions; (5) temporal reasoning to establish causal chronology; and (6) severity classification. Each stage introduces specific technical challenges amplified by the heterogeneous, institution-specific language of clinical documentation.

Rule-Based vs. Statistical vs. Deep Learning NLP Approaches

NLP methodologies for ADE extraction span three generations of technical sophistication. Rule-based systems employing hand-crafted lexicons, regular expressions, and grammatical patterns offer high precision for well-defined entities but limited recall and portability across institutions with different documentation styles. MedEx, cTAKES (clinical Text Analysis and Knowledge Extraction System), and NegEx exemplify rule-based tools deployed in clinical informatics. Statistical NLP models using conditional random fields (CRFs), maximum entropy classifiers, and structured perceptrons improved upon rule-based systems through data-driven feature learning, enabling better generalization across documentation styles. However, their reliance on handcrafted feature engineering limited scalability. Deep learning NLP models—and transformer-based architectures in particular—achieve substantial performance gains through end-to-end feature learning from large text corpora. Comparative studies across rule-based, statistical, and deep learning NLP approaches consistently demonstrate the superiority of transformer architectures on standard pharmacovigilance benchmarks. The SMM4H (Social Media Mining for Health) shared tasks, now in their eighth iteration, provide standardized evaluation platforms demonstrating progressive performance improvement aligned with architectural advances [Klein et al., 2024].

Graph Neural Network for Relational and Modeling

Drug-Drug Interaction Prediction

Polypharmacy—defined as the concurrent use of five or more medications—is both increasingly prevalent and a major ADR risk amplifier. A U.S. study estimates 22% of adults aged 40–79 receive five or more concurrent medications, with elderly populations experiencing the highest polypharmacy burden [Marques-Garcia et al., 2026]. Drug-drug interactions (DDIs) arising from polypharmacy can trigger unexpected pharmacological consequences including ADEs, toxicity, and even fatality [Li et al., 2024]. Graph Neural Networks (GNNs) offer a uniquely powerful paradigm for DDI and ADR prediction by natively representing drugs, patients, diseases, and adverse events as nodes within heterogeneous relational graphs, with edges encoding known interactions, therapeutic relationships, and causal linkages. The structural inductive bias of GNNs aligns with the inherently relational nature of pharmacological knowledge. GraphDDI, introduced at the AIiH 2024 conference, employs GNN architectures incorporating drug target knowledge and topological graph features to predict DDIs with demonstrated performance advantages over feature-based approaches [GraphDDI, 2024]. MGDDI (Multi-scale Graph neural network for DDI prediction) uses multi-scale graph convolutional layers combined with attention-based substructure interaction modules, capturing interaction details between drug pairs at multiple molecular scales [Geng et al., 2024]. AutoDDI employs neural architecture search to automatically discover optimal GNN configurations for DDI prediction, improving both accuracy and computational efficiency [Gao et al., 2024].

Patient-Level ADR Prediction via Heterogeneous GNNs

A significant limitation of earlier drug-centric ADR prediction approaches was their failure to account for individual patient heterogeneity—the reality that the same drug can elicit radically different responses across patients with differing demographics, comorbidities, genetic profiles, and medication histories. Heterogeneous GNN frameworks addressing patient-level ADR prediction represent the methodological frontier. PreciseADR, developed by Gao et al. at Zhejiang University (2024), introduces a patient-level ADR prediction framework leveraging heterogeneous GNNs that integrates relationships between patients, diseases, drugs, and ADRs as graph components [Gao et al., 2024]. Trained on the FDA Adverse Event Reporting System (FAERS) dataset, PreciseADR constructs a heterogeneous graph capturing patient disease burden, current medication regimens, and historical ADR patterns. The model captures both local neighborhood interactions and global graph-level dependencies, identifying subtle patterns predictive of ADR occurrence. Experimental results demonstrate PreciseADR outperforms the strongest baseline by 3.2% in AUC and 4.9% in Hit@10, validating the patient-level personalization approach. The PreciseADR architecture employs separate message-passing operations for different edge types (patient-drug, patient-disease, drug-ADR), followed by cross-type attention aggregation that dynamically weights information from different relation types based on predictive relevance. A statistical analysis of FAERS data incorporated within the model identifies ADR patterns associated with demographic subgroups defined by gender and age, enabling precision medicine-aligned risk stratification.

Explainable Ai in Clinical Adr Decision Support

The Black-Box Problem in Clinical AI

The deployment of high-performance but opaque "black-box" AI models in clinical settings faces a fundamental epistemological barrier: clinicians cannot responsibly act on predictions they cannot interpret, validate, or explain to patients. Regulatory frameworks—including FDA guidance on AI/ML-based medical devices and the EU's Medical Device Regulation—increasingly require interpretability as a precondition for clinical AI approval [Lavecchia, 2025]. This tension between predictive performance and transparency is the central challenge of translational clinical AI. The explainable AI (XAI) field addresses this challenge through post-hoc interpretation methods applied to trained models and intrinsically interpretable model architectures. Post-hoc methods include global explanation techniques quantifying overall feature importance distributions and local explanation methods providing instance-specific reasoning for individual predictions. Intrinsically interpretable alternatives include decision trees, logistic regression with regularization, and attention-mechanism-equipped neural networks.

SHAP and LIME for ADR Interpretability

SHAP (SHapley Additive exPlanations), grounded in cooperative game theory, computes each feature's marginal contribution to a specific prediction by systematically evaluating all possible feature coalitions. SHAP values satisfy desirable axioms including local accuracy, missingness, and consistency, making them theoretically well-founded. In ADR prediction models, SHAP analysis has been applied to identify which clinical variables—renal function, polypharmacy index, age—most strongly drive individual ADR risk estimates, enabling clinicians to understand and validate model reasoning [Salih et al., 2025]. LIME (Local Interpretable Model-agnostic Explanations) generates locally faithful explanations by fitting a simple linear model in the neighborhood of a specific prediction, approximating the decision boundary of complex models in a locally tractable manner. LIME is model-agnostic and applicable to any classifier or regressor, including deep learning architectures. Comparative evaluations indicate that SHAP generally outperforms LIME on consistency and robustness metrics while LIME provides simpler,  more concise explanations at higher interpretability thresholds [Salih et al., 2025; medRxiv, 2025]. Other XAI methods contributing to clinical ADR model transparency include: (1) Grad-CAM (Gradient-weighted Class Activation Mapping) for CNN-based visual and temporal models; (2) attention visualization for transformer architectures; (3) Partial Dependence Plots (PDPs) for global feature effects; and (4) counterfactual explanations indicating the minimum feature changes required to alter a prediction—the latter being particularly valuable for identifying modifiable risk factors amenable to clinical intervention The integration of XAI techniques into clinical decision support systems (CDSS) for ADR management is increasingly recognized as essential for regulatory compliance, clinician trust calibration, and medico-legal accountability. A comprehensive systematic review of AI-driven drug interaction prediction (147 studies, 2018–2024) emphasized the transformative role of SHAP, LIME, and attention mechanisms in enhancing clinical interpretability of complex graph and language models [systematic review, 2025].

Table 2. Comparative Overview of Explainable AI Methods for Clinical ADR Model

Pharmacogenomics And Precision Medicine Integration

Genetic Determinants of ADR Risk

Individual variability in drug response—and ADR susceptibility—is substantially determined by genetic polymorphisms affecting pharmacokinetic and pharmacodynamic pathways. Pharmacogenomics provides the mechanistic framework linking genotype to ADR phenotype. Key pharmacogenes influencing ADR risk include: CYP2D6 and CYP2C19 (cytochrome P450 enzymes governing metabolism of approximately 25% of marketed drugs); HLA alleles (HLA-B*57:01 associated with abacavir hypersensitivity; HLA-B*15:02 with carbamazepine-induced Stevens-Johnson syndrome); and transporters including OATP1B1 (statin-induced myopathy) and ABCB1 (multidrug resistance modulation). Multi-omics integration represents the next frontier in AI-driven ADR prediction. AI models incorporating genomics, transcriptomics, proteomics, and metabolomics alongside clinical EHR data provide the most complete picture of individual ADR risk. The DeepDRA model (2024) achieved a precision-recall AUC of 0.99 in drug response prediction using integrated multi-omics data, illustrating the performance ceiling attainable with comprehensive molecular profiling [Sciencedirect, 2025]. Key pharmacogenomic variants associated with antituberculosis drug-induced hepatotoxicity—including NAT2, OATP1B1 polymorphisms, and UGT1A1*27/*28—have been incorporated into ML models achieving AUC values of 0.89–0.90 [Lai et al., 2020].

 AI-Enhanced Pharmacogenomic Testing

Traditional preemptive pharmacogenomic testing focuses on single gene-drug pairs (e.g., TPMT before thiopurines, DPYD before fluoropyrimidines). AI models integrating multiple pharmacogenomic variants, drug-drug interaction predictions, and patient clinical profiles enable more holistic, personalized risk assessment. Clinical pharmacogenomics implementation studies have demonstrated strong value potential in optimizing common drugs including statins, anticoagulants, beta-blockers, and opioids—all major contributors to ADR-related hospitalizations [clinician experiences, 2024]. The convergence of AI and pharmacogenomics within clinical decision support frameworks enables prospective, genotype-informed prescribing recommendations. Primary care and tertiary care implementations of pre-emptive pharmacogenomic testing, supported by AI-driven drug interaction alerts, have demonstrated feasibility and clinical benefit. However, barriers including cost, turnaround time, clinician education, and reimbursement policies limit widespread adoption.

Data Sources and Ai Modelling Infrastructure

Electronic Health Records and Clinical Registries

Electronic Health Records represent the primary substrate for EHR-based ADR prediction modeling, providing longitudinal, multi-dimensional patient data including medication records, laboratory values, diagnoses (ICD codes), vital signs, clinical notes, and procedural records. A systematic review of AI-based pharmacoepidemiology models for ADE prediction found that 80% of included studies used only structured EHR or claims data, with 20% incorporating NLP components alongside structured data [Frontiers, 2026]. Large EHR repositories such as MIMIC-III/IV (Medical Information Mart for Intensive Care), the UK Biobank, and All of Us (NIH) provide rich, well-characterized datasets enabling model development and external validation. However, EHR data present well-documented quality challenges including missingness, inconsistent coding, confounding by indication, and incomplete capture of out-of-hospital medication use. Real-world evidence derived from insurance claims databases complements EHR data by providing longitudinal, population-level medication exposure records but lacks clinical granularity.

Spontaneous Reporting Databases

The FDA Adverse Event Reporting System (FAERS) represents the world's largest pharmacovigilance database, containing over 25 million individual case safety reports submitted since 1969. FAERS data—comprising patient demographics, suspect drugs, concomitant medications, reported reactions (MedDRA-coded), and outcomes—provide the primary substrate for signal detection AI and population-level ADR modeling. PreciseADR's FAERS-based training demonstrated the utility of this resource for patient-level heterogeneous GNN models [Gao et al., 2024].

WHO's VigiBase, maintained by the Uppsala Monitoring Centre, contains over 30 million individual case safety reports from 140 member countries and is the world's most comprehensive spontaneous reporting resource. VigiLyze, the AI-enhanced signal detection platform built on VigiBase, employs disproportionality analysis alongside predictive modeling to identify emerging safety signals. The EU's EudraVigilance and national pharmacovigilance databases (Yellow Card UK, BfArM Germany) provide regional complements to these global repositories.

Social Media and Patient-Generated Data

Social media platforms—Twitter/X, Reddit, MedHelp, WebMD forums—have emerged as real-time pharmacovigilance data sources providing patient-reported ADR experiences outside formal healthcare settings. Analyses suggest social media can detect ADR signals 2–3 months earlier than FAERS, reflecting patients' immediate digital reporting of adverse experiences. NLP models trained on social media ADR data must address unique challenges including informal language, abbreviations, negation ambiguity, and signal-to-noise ratios substantially lower than clinical text [Dong et al., 2024].

Table 3. Performance Benchmarks of Selected AI Models for ADR Prediction (2020–2025)